Phase 3 Studies Herald More Options for Metastatic Breast Cancer
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
A meta-analysis revealed inferior responses, progression-free survival, and overall survival in patients exposed to antibiotics.
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Enrollment rates varied widely by study type and institution.
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Dr Alan Lyss reviews studies of KRAS G12C mutations in metastatic colorectal cancer.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.